Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...
About the Grace Therapeutics Asset Portfolio GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet ...
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...
Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...
PRINCETON, N.J. - Grace Therapeutics, Inc. (NASDAQ:GRCE), a biopharmaceutical company focused on developing treatments for ...
13d
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 ...
About GTx-104 GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique ...
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. On its fourth attempt to pass muster with the FDA, the company’s SPN-830 ...
NIMOTOP (nimodipine) is a calcium channel blocker indicated for patients with subarachnoid hemorrhage. It improves neurological outcome by relaxing cerebral smooth muscle vasculature and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback